Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Neuromuscular Junction01:19

The Neuromuscular Junction

11.7K
The nervous system consists of complex motor neuron circuits, including upper motor neurons originating from the cerebral cortex and lower motor neurons starting in the spinal cord, coordinating both voluntary and involuntary movements. Among these, somatic motor neurons activate skeletal muscles and are classified into alpha, beta, and gamma types. Alpha neurons are vital for voluntary movement coordination, while gamma neurons adjust muscle spindle sensitivity, and the function of beta...
11.7K
Complement System01:27

Complement System

2.7K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.7K
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

3.7K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
3.7K
Chemical Synapses01:26

Chemical Synapses

9.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.2K
Relaxation of Skeletal Muscles01:29

Relaxation of Skeletal Muscles

3.8K
The period of muscle contraction primarily influences the duration of stimulation at the neuromuscular junction (NMJ), the presence of free calcium ions in the sarcoplasm, and the availability of energy or ATP to support contractions.
When an action potential reaches the axon terminal, it depolarizes the membrane and opens voltage-gated sodium channels. Sodium ions enter the cell, further depolarizing the presynaptic membrane. This depolarization causes voltage-gated calcium channels to open....
3.8K
Nervous System01:21

Nervous System

2.3K
The nervous system coordinates body functions through its complex network of nerve cells, enabling sensation and movement. It is divided into two primary parts: the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS is composed of the brain and the spinal cord. The brain acts as the body's control center, processing sensory information and coordinating responses. The spinal cord functions as a major signaling pathway for the brain and the rest of the body.
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Neurology. Clinical practice·2026
Same author

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

Journal of neurology·2026
Same author

Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial.

JAMA neurology·2026
Same author

Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Descartes-08: Unlocking the potential of mRNA CAR T-cell therapy in myasthenia gravis.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal.

European journal of neurology·2026

Related Experiment Video

Updated: Sep 15, 2025

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions
08:41

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions

Published on: August 14, 2021

8.9K

Neuromuscular junction and the complement system.

Saiju Jacob1, James F Howard2

  • 1Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom; University Hospitals Birmingham, Birmingham, United Kingdom.

International Review of Neurobiology
|July 17, 2025
PubMed
Summary

Complement inhibition shows promise for generalized myasthenia gravis (MG) by preventing acetylcholine receptor (AChR) antibody-induced neuromuscular junction damage. Therapies targeting complement protein 5 (C5) are advancing, with potential long-term benefits for MG patients.

Keywords:
C5ComplementEculizumabMyasthenia gravisRavulizumabZilucoplan

More Related Videos

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
11:03

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy

Published on: December 8, 2021

3.9K
Visualizing the Morphological Characteristics of Neuromuscular Junction in Rat Medial Gastrocnemius Muscle
08:42

Visualizing the Morphological Characteristics of Neuromuscular Junction in Rat Medial Gastrocnemius Muscle

Published on: May 17, 2022

4.5K

Related Experiment Videos

Last Updated: Sep 15, 2025

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions
08:41

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions

Published on: August 14, 2021

8.9K
Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
11:03

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy

Published on: December 8, 2021

3.9K
Visualizing the Morphological Characteristics of Neuromuscular Junction in Rat Medial Gastrocnemius Muscle
08:42

Visualizing the Morphological Characteristics of Neuromuscular Junction in Rat Medial Gastrocnemius Muscle

Published on: May 17, 2022

4.5K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Generalized myasthenia gravis (MG) is often caused by acetylcholine receptor (AChR) antibodies.
  • These antibodies trigger complement activation, leading to neuromuscular junction (NMJ) destruction via the membrane attack complex (MAC).
  • Experimental models confirm complement's role in MG pathogenesis.

Purpose of the Study:

  • To review the development and efficacy of complement inhibitory therapies for generalized myasthenia gravis.
  • To highlight the mechanisms of action and potential benefits of targeting the complement system in MG.
  • To discuss safety considerations and future directions for complement-based treatments in MG.

Main Methods:

  • Review of scientific literature on complement pathways in MG.
  • Analysis of experimental autoimmune MG (EAMG) models.
  • Summary of clinical trial data for anti-complement therapies targeting C5.

Main Results:

  • Nearly 90% of MG patients have IgG1 or IgG3 anti-AChR antibodies.
  • Complement inhibition, particularly C5 blockade, prevents MAC formation and NMJ destruction.
  • Several anti-complement therapies (eculizumab, zilucoplan, etc.) show long-term benefits in MG subgroups.
  • Vaccination and prophylactic antibiotics may be needed due to infection risk.

Conclusions:

  • Complement inhibition is a promising therapeutic strategy for generalized MG.
  • Targeting C5 effectively mitigates complement-mediated NMJ damage.
  • Further research into biomarkers may optimize patient selection for complement-based therapies.